#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Arterial disorder Chronic myeloid leukaemia Philadelphia positive chronic myeloid leukaemia Congenital nephrogenic diabetes insipidus Spinal muscular atrophy Optic glioma Conjunctivitis allergic Plasma cell myeloma Adenocarcinoma gastric Infantile spasms Philadelphia positive acute lymphocytic leukaemia Hepatic cirrhosis Malignant fibrous histiocytoma Enteritis Fibrosarcoma More trials…

    Learn about Rare Diseases

    Cytokine release syndrome – Treatment Glycogen storage disease type II – Life with Disease Waldenstrom’s macroglobulinaemia recurrent – Basic Information Short-bowel syndrome Encephalitis autoimmune Alexander disease – Diagnostics Hepatoblastoma Adrenocortical carcinoma – Diagnostics Advanced systemic mastocytosis – Diagnostics Propionic acidaemia – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Ziltivekimab Sacituzumab Govitecan Gadoteric Acid Lithium Magnesium Chloride Tramadol Atomoxetine Hydrochloride Mps-215 Ck-0045 4-Hydroxy-N-Desmethyltamoxifen Clonidine Hydrochloride Nmd670 Lasofoxifene Tak-280 Water For Injections Crinecerfont Gemlapodect Alclometasone Dipropionate Brepocitinib Tosilate Mirodenafil Dihydrochloride More therapies…

    Learn about Your Condition

    Traumatic pain Autoimmune hepatitis Cluster headache Familial mediterranean fever Injection site pain Compulsive sexual behaviour Knee arthroplasty Hepatitis D Breast cancer metastatic Choroidal dystrophy Atrial septal defect Peripheral artery thrombosis Encephalitis Japanese B Radiation skin injury Spina bifida More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Duchenne muscular dystrophy

  • Study on the Safety and Effects of Delandistrogene Moxeparvovec in Children Under 4 with Duchenne Muscular Dystrophy

    Not recruiting

    2 1 1
    Investigated Drugs:
    • Delandistrogene Moxeparvovec
    Belgium France Germany Italy Spain

  • Study on the Effects of Satralizumab in Children and Adolescents with Duchenne Muscular Dystrophy

    Not recruiting

    2 1 1
    Denmark Italy Poland Spain

  • Study on DMD06-MAB Injection for Duchenne Muscular Dystrophy in Non-Ambulant Patients

    Not recruiting

    2 1 1
    Investigated Drugs:
    • Dmd06-Mab
    Italy

  • Study on Long-Term Safety and Effectiveness of Vamorolone in Boys with Duchenne Muscular Dystrophy Who Completed Previous Vamorolone Studies

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Duchenne muscular dystrophy
    Investigated Drugs:
    • Vamorolone
    Belgium Czechia Greece Ireland The Netherlands Spain

  • Study on Eteplirsen for Patients with Duchenne Muscular Dystrophy with Deletion Mutations Amenable to Exon 51 Skipping

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Duchenne muscular dystrophy
    Investigated Drugs:
    • Eteplirsen
    Czechia Denmark France Germany Greece Hungary +7

  • Study on the Safety and Efficacy of Viltolarsen for Boys with Duchenne Muscular Dystrophy

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Viltolarsen
    Czechia Greece Italy The Netherlands Norway Spain
Previous Page
1 2 3 4 5
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!